Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
1.
Arch. endocrinol. metab. (Online) ; 61(6): 633-636, Dec. 2017. graf
Article Dans Anglais | LILACS | ID: biblio-887602

Résumé

SUMMARY Isolated growth hormone deficiency (IGHD) is the most common pituitary hormone deficiency and, clinically, patients have delayed bone age. High sequence similarity between CYP21A2 gene and CYP21A1P pseudogene poses difficulties for exome sequencing interpretation. A 7.5 year-old boy born to second-degree cousins presented with severe short stature (height SDS −3.7) and bone age of 6 years. Clonidine and combined pituitary stimulation tests revealed GH deficiency. Pituitary MRI was normal. The patient was successfully treated with rGH. Surprisingly, at 10.8 years, his bone age had advanced to 13 years, but physical exam, LH and testosterone levels remained prepubertal. An ACTH stimulation test disclosed a non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency explaining the bone age advancement and, therefore, treatment with cortisone acetate was added. The genetic diagnosis of a homozygous mutation in GHRHR (p.Leu144His), a homozygous CYP21A2 mutation (p.Val282Leu) and CYP21A1P pseudogene duplication was established by Sanger sequencing, MLPA and whole-exome sequencing. We report the unusual clinical presentation of a patient born to consanguineous parents with two recessive endocrine diseases: non-classic congenital adrenal hyperplasia modifying the classical GH deficiency phenotype. We used a method of paired read mapping aided by neighbouring mis-matches to overcome the challenges of exome-sequencing in the presence of a pseudogene.


Sujets)
Humains , Mâle , Nourrisson , Enfant , Dysplasies osseuses/génétique , Steroid 21-hydroxylase/génétique , Récepteur aux neuropeptides/génétique , Hyperplasie congénitale des surrénales/génétique , Nanisme hypophysaire/génétique , Pedigree , Phénotype , Dysplasies osseuses/étiologie , Récepteur hormones hypothalamiques hypophysotropes régulatrices/génétique , Hyperplasie congénitale des surrénales/complications , Consanguinité , Nanisme hypophysaire/complications , Mutation
2.
Clinics ; 67(3): 265-272, 2012. graf, tab
Article Dans Anglais | LILACS | ID: lil-623102

Résumé

OBJECTIVE: To investigate a possible direct, growth hormone-releasing, hormone-independent action of a growth hormone secretagogue, GHRP-2, in pituitary somatotroph cells in the presence of inactive growth hormonereleasing hormone receptors. MATERIALS AND METHODS: The responses of serum growth hormone to acutely injected growth hormone-releasing P-2 in lit/litmice, which represent a model of GH deficiency arising frommutated growth hormone-releasing hormonereceptors, were compared to those observed in the heterozygous (lit/+) littermates and wild-type (+/+) C57BL/6J mice. RESULTS: After the administration of 10 mcg of growth hormone-releasing P-2 to lit/lit mice, a growth hormone release of 9.3±1.5 ng/ml was observed compared with 1.04±1.15 ng/ml in controls (p<0.001). In comparison, an intermediate growth hormone release of 34.5±9.7 ng/ml and a higher growth hormone release of 163±46 ng/ml were induced in the lit/+ mice and wild-type mice, respectively. Thus, GHRP-2 stimulated growth hormone in the lit/lit mice, and the release of growth hormone in vivo may be only partially dependent on growth hormone-releasing hormone. Additionally, the plasma leptin and ghrelin levels were evaluated in the lit/lit mice under basal and stimulated conditions. CONCLUSIONS: Here, we have demonstrated that lit/lit mice, which harbor a germline mutation in the Growth hormone-releasing hormone gene, maintain a limited but statistically significant growth hormone elevation after exogenous stimulation with GHRP-2. The present data probably reflect a direct, growth hormone-independent effect on Growth hormone S (ghrelin) stimulation in the remaining pituitary somatotrophs of little mice that is mediated by growth hormone S-R 1a.


Sujets)
Animaux , Femelle , Mâle , Souris , Hormone de croissance/métabolisme , Oligopeptides/pharmacologie , Récepteur aux neuropeptides/génétique , Récepteur hormones hypothalamiques hypophysotropes régulatrices/génétique , Analyse de variance , Modèles animaux de maladie humaine , Ghréline/sang , Hormone de croissance/déficit , Hétérozygote , Leptine/sang , Souches mutantes de souris , Oligopeptides/administration et posologie , Répartition aléatoire
3.
Arq. bras. endocrinol. metab ; 48(3): 406-413, jun. 2004. ilus, tab
Article Dans Portugais | LILACS | ID: lil-365164

Résumé

Além de influenciar o crescimento corpóreo, o hormônio do crescimento, ou somatotrófico, desempenha importante papel no metabolismo, composição corporal, perfil lipídico, estado cardiovascular e longevidade. Seu controle é multi-regulado por hormônios, metabólitos e peptídeos hipotalâmicos. Dados sobre a Deficiência Isolada de GH (DIGH) obtidos a partir da descrição da mutação IVS1+1G®A no gene do receptor do hormônio liberador do GH (GHRH-R) em indivíduos da cidade de Itabaianinha, SE, são revisados. São abordadas novas perspectivas sobre o modelo de resistência ao GHRH, a importância do GHRH no controle da secreção de GH, a freqüência das mutações do gene do GHRH-R, a relevância diagnóstica do IGF-I e os achados metabólicos, cardiovasculares e de qualidade de vida nestes indivíduos.


Sujets)
Adolescent , Adulte , Enfant , Humains , Adulte d'âge moyen , Hormone de croissance/déficit , Récepteur aux neuropeptides/génétique , Récepteur hormones hypothalamiques hypophysotropes régulatrices/génétique , Brésil , Hormone de libération de l'hormone de croissance/physiologie , Facteur de croissance IGF-I/physiologie , Mutation
SÉLECTION CITATIONS
Détails de la recherche